Linked Data API

Show Search Form

Search Results

1007839
registered interest false more like this
date remove filter
answering body
Home Office more like this
answering dept id 1 more like this
answering dept short name Home Office more like this
answering dept sort name Home Office more like this
hansard heading National Economic Crime Centre more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for the Home Department, how the National Economic Crime Centre is planned to help increase the number of prosecutions for crimes such as bribery and corruption. more like this
tabling member constituency Hendon more like this
tabling member printed
Dr Matthew Offord more like this
uin 191903 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-23more like thismore than 2018-11-23
answer text <p>The National Economic Crime Centre (NECC) will deliver a step change in the UK's response to - and impact on economic crime, including bribery and corruption.</p><p>For the first time, the NECC brings together enforcement and justice agencies (HM Revenue and Customs, the City of London Police, the National Crime Agency, the Serious Fraud Office and the Crown Prosecution Service), other government departments, regulatory bodies and the private sector with a shared objective of driving down economic crime in the UK.</p><p>It will leverage the 'whole system' approach to enhance and coordinate our collective capabilities to target, pursue and dismantle the highest harm serious and organised criminals, including corrupt elites. Where appropriate this will include prosecutions.</p> more like this
answering member constituency Wyre and Preston North more like this
answering member printed Mr Ben Wallace more like this
question first answered
less than 2018-11-23T12:12:03.047Zmore like thismore than 2018-11-23T12:12:03.047Z
answering member
1539
label Biography information for Mr Ben Wallace more like this
tabling member
4006
label Biography information for Dr Matthew Offord more like this
1007797
registered interest false more like this
date remove filter
answering body
Department for Exiting the European Union more like this
answering dept id 203 more like this
answering dept short name Exiting the European Union more like this
answering dept sort name Exiting the European Union more like this
hansard heading Department for Exiting the European Union: Labour Turnover more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Exiting the European Union, what estimate he has made of the number of staff who have left his Department since it was created; and what information his Department holds on the reasons for those departures. more like this
tabling member constituency Coventry South more like this
tabling member printed
Mr Jim Cunningham more like this
uin 191861 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-20more like thismore than 2018-11-20
answer text <p>The Department for Exiting the European Union was set up as a time limited department and as such the majority of staff are employed on fixed term contracts or are loaned from other Government Departments. Attrition has remained stable at about 3% monthly average for most of the department’s life. These figures are not considered out of line for a department that has a staff profile as above. Many of those who have left to date have been planned leavers who have moved to other government departments due to their loan or job rotation coming to an end.</p><p> </p> more like this
answering member constituency Worcester more like this
answering member printed Mr Robin Walker more like this
question first answered
less than 2018-11-20T16:27:03.767Zmore like thismore than 2018-11-20T16:27:03.767Z
answering member
4091
label Biography information for Mr Robin Walker more like this
tabling member
308
label Biography information for Mr Jim Cunningham more like this
1007757
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Levetiracetam more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy. more like this
tabling member constituency Crewe and Nantwich more like this
tabling member printed
Laura Smith more like this
uin 191984 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-22more like thismore than 2018-11-22
answer text <p>The United Kingdom’s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.</p><p> </p><p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-22T11:54:10.717Zmore like thismore than 2018-11-22T11:54:10.717Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4648
label Biography information for Laura Smith more like this
1007767
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Nusinersen more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 191928 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-22more like thismore than 2018-11-22
answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).</p><p> </p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.</p><p> </p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE’s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-22T15:13:09.58Zmore like thismore than 2018-11-22T15:13:09.58Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
1007772
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading HIV Infection: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial. more like this
tabling member constituency Rotherham more like this
tabling member printed
Sarah Champion more like this
uin 191929 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-20more like thismore than 2018-11-20
answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
191930 more like this
191931 more like this
191932 more like this
question first answered
less than 2018-11-20T15:03:05.303Zmore like thismore than 2018-11-20T15:03:05.303Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4267
label Biography information for Sarah Champion more like this
1007773
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading HIV Infection: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis. more like this
tabling member constituency Rotherham more like this
tabling member printed
Sarah Champion more like this
uin 191930 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-20more like thismore than 2018-11-20
answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
191929 more like this
191931 more like this
191932 more like this
question first answered
less than 2018-11-20T15:03:05.35Zmore like thismore than 2018-11-20T15:03:05.35Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4267
label Biography information for Sarah Champion more like this
1007775
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading HIV Infection: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date. more like this
tabling member constituency Rotherham more like this
tabling member printed
Sarah Champion more like this
uin 191931 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-20more like thismore than 2018-11-20
answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
191929 more like this
191930 more like this
191932 more like this
question first answered
less than 2018-11-20T15:03:05.407Zmore like thismore than 2018-11-20T15:03:05.407Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4267
label Biography information for Sarah Champion more like this
1007776
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading HIV Infection: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date. more like this
tabling member constituency Rotherham more like this
tabling member printed
Sarah Champion more like this
uin 191932 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-20more like thismore than 2018-11-20
answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
191929 more like this
191930 more like this
191931 more like this
question first answered
less than 2018-11-20T15:03:05.453Zmore like thismore than 2018-11-20T15:03:05.453Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4267
label Biography information for Sarah Champion more like this
1007777
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will introduce a secondary support package covering breast cancer care to include (a) access to a dedicated clinical nurse specialist, (b) an assessment of physical and emotional needs at (i) diagnosis and (ii) through treatment and referral and (c) signposting to tailored, specialist support services. more like this
tabling member constituency Birkenhead more like this
tabling member printed
Frank Field more like this
uin 191871 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-22more like thismore than 2018-11-22
answer text <p>The NHS Cancer Programme is working to improve access to cancer nurse specialists (CNSs) for all cancer patients when they need it, including those with secondary breast cancer.</p><p> </p><p>We are committed to rolling out the recovery package to every cancer patient by 2020. The recovery package is a set of four interventions designed to help patients and clinicians assess a patient’s holistic needs, including physical and emotional needs, at appropriate time points through their cancer journey, as needs do change especially when a person is diagnosed with secondary cancer. A personalised care and support plan to meets these needs should be agreed, ensuring signposting and referral to the right support and care services is made, and also helping to empower patients to independently manage their own health, with advice and support.</p><p> </p><p>NHS England is committed to giving more patients access to a CNS or other specialist from diagnosis onwards to guide them through treatment options and ensure they receive appropriate information and support. In their first Cancer Workforce Plan, which was published in December 2017, Health Education England committed to supporting the expansion of CNSs by developing national competencies and a clear route into training. This will ensure that every patient has access to a CNS or other support worker by 2021.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-22T15:20:10.943Zmore like thismore than 2018-11-22T15:20:10.943Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
478
label Biography information for Frank Field more like this
1007788
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Prescriptions: Fees and Charges more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many prescription items were dispensed for free in each exemption category in the last period for which figures are available. more like this
tabling member constituency Cleethorpes more like this
tabling member printed
Martin Vickers more like this
uin 191902 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-22more like thismore than 2018-11-22
answer text <p>The information is not held in the format requested.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-22T15:11:14.177Zmore like thismore than 2018-11-22T15:11:14.177Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
3957
label Biography information for Martin Vickers more like this